Search by Drug Name or NDC
NDC 42546-0279-06 Salicylic Acid 6 percent 6 mg/100mL Details
Salicylic Acid 6 percent 6 mg/100mL
Salicylic Acid 6 percent is a TOPICAL SHAMPOO in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by PruGen LLC. The primary component is SALICYLIC ACID.
MedlinePlus Drug Summary
Topical salicylic acid is used to help clear and prevent pimples and skin blemishes in people who have acne. Topical salicylic acid is also used to treat skin conditions that involve scaling or overgrowth of skin cells such as psoriasis (a skin disease in which red, scaly patches form on some areas of the body), ichthyoses (inborn conditions that cause skin dryness and scaling), dandruff, corns, calluses, and warts on the hands or feet. Topical salicylic acid should not be used to treat genital warts, warts on the face, warts with hair growing from them, warts in the nose or mouth, moles, or birthmarks. Salicylic acid is in a class of medications called keratolytic agents. Topical salicylic acid treats acne by reducing swelling and redness and unplugging blocked skin pores to allow pimples to shrink. It treats other skin conditions by softening and loosening dry, scaly, or thickened skin so that it falls off or can be removed easily.
Related Packages: 42546-0279-06Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Salicylic Acid Topical
Product Information
NDC | 42546-0279 |
---|---|
Product ID | 42546-279_45777b6d-68da-4e50-9613-dfeb5633d965 |
Associated GPIs | 90750030004530 |
GCN Sequence Number | 061504 |
GCN Sequence Number Description | salicylic acid SHAMPOO 6 % TOPICAL |
HIC3 | L5A |
HIC3 Description | KERATOLYTICS |
GCN | 97292 |
HICL Sequence Number | 002465 |
HICL Sequence Number Description | SALICYLIC ACID |
Brand/Generic | Generic |
Proprietary Name | Salicylic Acid 6 percent |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Salicylic Acid |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | SHAMPOO |
Route | TOPICAL |
Active Ingredient Strength | 6 |
Active Ingredient Units | mg/100mL |
Substance Name | SALICYLIC ACID |
Labeler Name | PruGen LLC |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | UNAPPROVED DRUG OTHER |
Application Number | n/a |
Listing Certified Through | 2024-12-31 |
Package
Package Images

NDC 42546-0279-06 (42546027906)
NDC Package Code | 42546-279-06 |
---|---|
Billing NDC | 42546027906 |
Package | 1 BOTTLE in 1 BOX (42546-279-06) / 177 mL in 1 BOTTLE |
Marketing Start Date | 2009-01-01 |
NDC Exclude Flag | N |
Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL b66252b0-84b5-45fc-a5f4-fd35dd341e73 Details
SPL UNCLASSIFIED SECTION
DESCRIPTION
SHAMPOO contains 6% w/w salicylic acid USP in a vehicle composed of purified water, disodium laureth sulfosuccinate, cocamidopropyl betaine, hexylene glycol, linoleamidpropyl PG-dimonium chloride phosphate, polyquaternium-22, propylene glycol, sodium C14-16 olefin sulfonate, sodium citrate, sodium lauryl sarcosinate, tetrasodium EDTA, tocopherol acetate and fragrance.
Salicylic acid is the 2-hydroxy derivative of benzoic acid having the following structure:

CLINICAL PHARMACOLOGY
Salicylic acid has been shown to produce desquamation of the horny layer of skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of inter cellular cement substance.
In a study of the percutaneous absorption of salicylic acid in a 6%salicylic acid gel in four patients with extensive active psoriasis, Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100 ml).
Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extra cellular space, patients with a contracted extra cellular space due to dehydration or diuretics have a higher salicylate levels than those with a normal extra cellular space. (See PRECAUTIONS)
The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space.
Fifty to eighty percent of a salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the actions of these drugs; by similar competitive mechanisms other drugs can influence the serum levels of salicylate.(See PRECAUTIONS)
INDICATIONS AND USAGE
For Dermatologic Use
Salicylic Acid 6% (w/w) Shampoo is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).
CONTRAINDICATIONS
WARNINGS
Prolonged use over large areas, especially in children and those patients with significant renal or hepatic impairment could resultin salicylism. Excessive application of the product other than is needed to cover the affected area will not result in more therapeutic benefit. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal or hepatic impairment, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances. In the event of salicylic acid toxicity, the use of the Salicylic Acid 6% (w/w) Shampoo should be discontinued. Fluids should be administered to promote urinary excretion. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports and injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal, anti-inflammatory agent that is not salicylate based.
Due to potential risk of developing Reye's syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by a physician.
PRECAUTIONS
For external use only. Avoid contact with eyes and other mucous membranes.
DRUG INTERACTIONS
The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of Salicylic Acid 6% (w/w) Shampoo is not known.
I.Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:
DRUG | DESCRIPTION OF INTERACTION |
---|---|
Sulfonylureas | Hypoglycemia potentiated. |
Methotrexate | Decreases tubular reabsorption; clinical toxicity from methotrexate can result. |
Oral Anticoagulants | Increased bleeding. |
II.Drugs changing salicylate levels by altering renal tubular reabsorption:
DRUG | DESCRIPTION OF INTERACTION |
---|---|
Corticosteroids | Decreases plasma salicylate level; tapering doses of steroids may promote salicylism. |
Acidifying Agents | Increases plasma salicylate level. |
Alkanizing Agents | Decreased plasma salicylate levels. |
III.Drugs with complicated interactions with salicylates:
DRUG | DESCRIPTION OF INTERACTION |
---|---|
Heparin | Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin treated patients. |
Pyrazinamide | Inhibits pyrazinamide-induced hyperuricemia. |
Uricosuric | Effect of probenemide, sulfinpyrazone and phenylbutazone inhibited. |
The following alterations of laboratory tests have been reported during salicylate therapy:
LABORATORY TESTS | EFFECT OF SALICYLATES |
---|---|
Thyroid Function | Decreased PBI; increased T3 uptake. |
Urinary Sugar | False negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g q.d.). |
5- Hydroxyindole acetic acid | False negative with fluorometric test. |
Acetone, ketone bodies | False positive FeCl3 in Gerhardt reaction; red color persists with boiling |
.17-OH corticosteroids | False reduced values with >4.8g q.d. salicylate. |
Vanilmandelic acid | False reduced values. |
Uric acid | May increase or decrease depending ondose. |
Prothrombin | Decreased levels; slightly increased prothrombin time. |
Pregnancy (Category C)
Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. Salicylic Acid 6% (w/w) Shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
Because of the potential for serious adverse reactions in nursing infants from the mother's use of Salicylic Acid 6% (w/w) Shampoo, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If used by nursing mothers, it should not be used on the chest area to avoid the accidental contamination of the child.
ADVERSE REACTIONS
OVERDOSAGE
See WARNINGS.
DOSAGE AND ADMINISTRATION
HOW SUPPLIED
SPL UNCLASSIFIED SECTION
PRINCIPAL DISPLAY PANEL - 177 ml Bottle Box
INGREDIENTS AND APPEARANCE
SALICYLIC ACID 6 PERCENT
salicylic acid shampoo |
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Labeler - PruGen LLC (929922750) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
EMS ACQUISITION CORP. | 048602791 | MANUFACTURE(42546-279) |